Graham Goodrich

Chief Commercial Officer

Graham Goodrich joined Apnimed as Chief Commercial Officer in January, 2024. He has an extensive track record of commercial success in launching and marketing transformative brands. As a member of the Commercial leadership team and SVP of Migraine Marketing at Biohaven, Graham led a team that developed a novel brand strategy, go-to-market model and promotion plan to launch Nurtec(r) ODT in the midst of the Covid-19 pandemic. After a successful launch and achieving category leadership, Pfizer acquired the Biohaven Migraine franchise assets and capabilities in October, 2022 for $11.6B. Post-acquisition, Goodrich served as the US Migraine Franchise Lead at Pfizer throughout 2023.

Prior to Biohaven, Goodrich held the role of VP, Cardiometabolic Marketing at Boehringer Ingelheim and was the leader of a diverse portfolio of pre-launch, newly-launched and mature cardiometabolic assets including Jardiance, Tradjenta, Basaglar and Pradaxa, totaling over $3.5B in annual new sales. In all, Graham has more than 25 years of experience working on iconic, blockbuster brands in neurology, respiratory, immunology and cardiometabolic health. He received his MBA from the University of Michigan, and his BS from Wake Forest University.